Targeted therapies in gastric cancer and future perspectives

Table 3 Ongoing Phase II and III studies

Target	Agents	Trial number	Setting	Phase	Primary end point	Status
HER-2	Arm A: pertuzumab + trastuzumab + cisplatin + fluoropyrimidine vs Arm B: placebo + trastuzumab + cisplatin + fluoropyrimidine	NCT01774786	First line	III	OS	Recruiting
HER-2	Arm A: Docetaxel or paclitaxel	NCT01641939	First line	II/III	Phase II: Dose of TDM-1	Recruiting
	Arm B: T-DM1 3.6 mg/kg every 3 wk
	Arm C: T-DM1 2.4 mg/kg once a week				Phase III: OS
HER-3	Arm A: MM-111 + Paclitaxel + Trastuzumab	NCT01774851	≥ Second line	II	PFS	Active, not recruiting
	Arm B: Paclitaxel + Trastuzumab
MET	Arm A: Rilotumumab 15 mg/kg plus ECX	NCT01697072	First line	III	OS	Active, not recruiting
	Arm B: Placebo plus ECX
MET	Arm A: onartuzumab plus mFOLFOX6	NCT01662869	First line	III	OS	Active, not recruiting
	Aram B: placebo plus mFOLFOX6
CTLA4	Arm A: Ipilimumab	NCT01585987	Maintanence	II	PFS	Active, not recruiting
	Arm B: Best Supportive Care
PD-1	Arm A: Nivolumab (ONO-4538)	NCT02267343	≥ Second line	III	OS	Recruiting
	Arm B: Placebo

CTLA4: Cytotoxic T lymphocyte antigen; PD-1: Programmed cell death.